Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2014; 20(6): 1565-1573
Published online Feb 14, 2014. doi: 10.3748/wjg.v20.i6.1565
Published online Feb 14, 2014. doi: 10.3748/wjg.v20.i6.1565
Table 2 Treatment characteristics according to hematological toxicity in 399 consecutive patients with metastatic colorectal cancer n (%)
| All (n = 399) | Anemia (n= 397) | Neutropenia (n= 396) | Thrombopenia (n= 396) | ||||||||||||||
| No (n= 33) | Yes (n= 364) | P | No (n= 114) | Yes (n= 282) | P | No (n= 163) | Yes (n= 233) | P | |||||||||
| Lines of chemotherapy | 0.3 | < 10-4 | 0.053 | ||||||||||||||
| < 2 | 46 | (11.5) | 2 | (6.1) | 44 | (12.1) | 25 | (21.9) | 21 | (7.4) | 25 | (15.3) | 21 | (9) | |||
| ≥ 2 | 353 | (88.5) | 31 | (93.9) | 320 | (87.9) | 89 | (78.1) | 261 | (92.6) | 138 | (84.7) | 212 | (91) | |||
| Lines of chemotherapy | |||||||||||||||||
| n | 399 | 33 | 364 | 114 | 282 | 163 | 233 | ||||||||||
| Mean ± SD | 4.4 ± 2.5 | 5 ± 2.8 | 4.4 ± 2.5 | 0.266 | 3.4 ± 2.1 | 4.9 ± 2.6 | < 10-4 | 3.9 ± 2.4 | 4.9 ± 2.6 | < 10-4 | |||||||
| Median (min-max) | 4 (1-13) | 4 (1-11) | 4 (1-13) | 3 (1-9) | 5 (1-13) | 3 (1-12) | 5 (1-13) | ||||||||||
| Number of drugs | 0.760 | < 10-4 | < 10-3 | ||||||||||||||
| 1 | 20 | (5) | 2 | (6.1) | 18 | (4.9) | 13 | (11.4) | 7 | (2.5) | 15 | (9.2) | 5 | (2.1) | |||
| 2 | 79 | (19.8) | 5 | (15.2) | 74 | (20.3) | 34 | (29.8) | 45 | (16.0) | 42 | (25.8) | 37 | (15.9) | |||
| 3 | 300 | (75.2) | 26 | (78.8) | 272 | (74.7) | 67 | (58.8) | 230 | (81.6) | 106 | (65.0) | 191 | (82.0) | |||
| Bevacizumab | 0.613 | 0.022 | 0.245 | ||||||||||||||
| Yes | 226 | (57.1) | 17 | (53.1) | 209 | (57.7) | 54 | (48.2) | 171 | (60.9) | 86 | (53.8) | 139 | (59.7) | |||
| No | 170 | (42.9) | 15 | (46.9) | 153 | (42.3) | 58 | (51.8) | 110 | (39.1) | 74 | (46.3) | 94 | (40.3) | |||
| Missing | 3 | 1 | 2 | 2 | 1 | 3 | 0 | ||||||||||
| Anti- EGFR mab | 0.789 | 0.004 | 0.096 | ||||||||||||||
| Yes | 165 | (41.6) | 14 | (43.8) | 150 | (41.3) | 34 | (30.4) | 130 | (46.1) | 59 | (36.6) | 105 | (45.1) | |||
| No | 232 | (58.4) | 18 | (56.3) | 213 | (58.7) | 78 | (69.6) | 152 | (53.9) | 102 | (63.4) | 128 | (54.9) | |||
| Missing | 2 | 1 | 1 | 2 | 0 | 2 | 0 | ||||||||||
| Granulocyte-colony stimulating factor use | 0.838 | < 10-4 | 0.003 | ||||||||||||||
| Yes | 105 | (26.7) | 9 | (28.1) | 95 | (26.5) | 10 | (9.2) | 94 | (33.5) | 30 | (18.8) | 74 | (32.2) | |||
| No | 288 | (73.3) | 23 | (71.9) | 264 | (73.5) | 99 | (90.8) | 187 | (66.5) | 130 | (81.3) | 156 | (67.8) | |||
| Missing | 6 | 1 | 5 | 5 | 1 | 3 | 3 | ||||||||||
| EPO use | 0.049 | 0.57 | 0.41 | ||||||||||||||
| Yes | 76 | (19.4) | 2 | (6.3) | 74 | (20.7) | 23 | (21.1) | 52 | (18.6) | 34 | (21.3) | 41 | (17.9) | |||
| No | 316 | (80.6) | 30 | (93.8) | 284 | (79.3) | 86 | (78.9) | 228 | (81.4) | 126 | (78.8) | 188 | (82.1) | |||
| Missing | 7 | 1 | 6 | 5 | (4.6) | 2 | 3 | 4 | |||||||||
| Surgery of primary tumor | 0.052 | 0.059 | 0.487 | ||||||||||||||
| Yes | 323 | (81.2) | 31 | (93.9) | 291 | (80.2) | 86 | (75.4) | 235 | (83.6) | 129 | (79.6) | 192 | (82.4) | |||
| No | 75 | (18.8) | 2 | (6.1) | 72 | (19.8) | 28 | (24.6) | 46 | (16.4) | 33 | (20.4) | 41 | (17.6) | |||
| Missing | 1 | 0 | 1 | 0 | 1 | 1 | 0 | ||||||||||
| Surgery of metastatic site | 0.148 | 0.007 | 0.001 | ||||||||||||||
| Yes | 102 | (25.7) | 13 | (40.6) | 103 | (28.4) | 22 | (19.6) | 94 | (33.3) | 33 | (20.4) | 83 | (35.8) | |||
| No | 295 | (74.3) | 19 | (59.4) | 260 | (71.6) | 90 | (80.4) | 188 | (66.7) | 129 | (79.6) | 149 | (64.2) | |||
| Missing | 2 | 1 | 1 | 2 | 0 | 1 | 1 | ||||||||||
- Citation: Rambach L, Bertaut A, Vincent J, Lorgis V, Ladoire S, Ghiringhelli F. Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. World J Gastroenterol 2014; 20(6): 1565-1573
- URL: https://www.wjgnet.com/1007-9327/full/v20/i6/1565.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i6.1565